NantKwest Inc. (NK) had a rough trading day for Wednesday December 19 as shares tumbled 8%, or a loss of $-0.1 per share, to close at $1.15. After opening the day at $1.24, shares of NantKwest Inc. traded as high as $1.30 and as low as $1.12. Volume was 257,346 shares over 1,534 trades, against an average daily volume of n/a shares and a total float of 79.23 million.
As a result of the decline, NantKwest Inc. now has a market cap of $91.11 million. In the last year, shares of NantKwest Inc. have traded between a range of $5.47 and $1.09, and its 50-day SMA is currently $n/a and 200-day SMA is $n/a.
NantKwest Inc is a United States-based firm functioning in the healthcare sector. It is focused on providing immunotherapeutic agents, especially natural killer cells to treat cancer, infectious and inflammatory diseases. Natural Killer (NK) cells are ancient cells in the human body designed to recognize and detect cells under stress or infected. The company’s drug candidates such as activated NK cells, high-affinity NKs and target activated NK’s address virally-induced cancers, viral, fungal and bacterial infections as well as critical diseases such as Ebola. Its pipeline product includes taNK, haNK, and aNK. Most of NatWest’s sales are concentrated in the United States region although it has a reasonable market in Europe and other Non-U.S territories.
NantKwest Inc. is based out of San Diego, CA and has some 184 employees. Its CEO is Patrick Soon-Shiong.
